insights_auto
Prečo akcie NZM2 stúpli 2,62%?
Preskúmať podrobnejšiechevron_right
NZM2:ETR
Novozymes A/S
59,52 €
arrow_upward
+2,62%(+1,52) 1 d.
13. 10., 9:04:32 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre NZM2…
Otvoriť
59,52 €
Vysoká
59,52 €
Nízka
59,52 €
Trh. kap.
180,41 mld.
Priem. obj.
120,00
Objem
1,00
Max. za 52 týž.
61,96 €
Min. za 52 týž.
46,74 €
Počet zamestnancov
11 tis.
Otvoriť
59,52 €
Vysoká
59,52 €
Nízka
59,52 €
Trh. kap.
180,41 mld.
Priem. obj.
120,00
Objem
1,00
Max. za 52 týž.
61,96 €
Min. za 52 týž.
46,74 €
Počet zamestnancov
11 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
StreetInsider
·
pred 1 dňom
Transactions under Novonesis’ share buyback program
Profil
Novonesis is a biotechnology company headquartered in Lyngby, Denmark. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen.
The company develops enzymes, microbial cultures, and other biological products used in food and beverage production, household products, agriculture, and bioenergy.
The merger, first announced in December 2022, was the largest merger in history between two Danish companies. It would combine Novozymes' industrial-enzyme business with Chr. Hansen's microbial cultures and food-ingredient operations.
The company is publicly traded on Nasdaq Copenhagen and is part of the OMX Copenhagen 25 Index. The company's largest shareholder is Novo Holdings A/S, which is owned by the Novo Nordisk Foundation.
As of 2025, Novonesis has more than 11,000 employees and activities in over 45 countries. Wikipedia
Informácie o subjekte Novozymes A/S
Generálny riaditeľEster Baiget
Zamestnanci11,1 tis.
Dátum založenia2000
Hlavné sídlo-
OdvetvieSpeciality chemicals